• Teaser
  • Kapseln
  • Teaser
  • Teaser

GMP Chitosan, medical device chitosan, pure chitin, pharma chitosan, chitosan derivatives, GMP, Quality, producer | Heppe Medical Chitosan

Respirators with chitosan nanoparticles as protection against SARS-CoV-2 infection

In the current corona pandemic, the protection of medical personnel who have contact with Covid-19 infected patients is important, also to ensure stability of the health care services. The personal protective equipment of hospital staff includes particle filtering respiratory masks. From early 2021, a clinical study will be conducted to investigate the protective effect of a new type of respirator with a filter element containing chitosan nanoparticles in Brazil. More about this study and other current clinical studies with chitosan in this article.

Chitosan for pulmonary applications

Chitosan is a promising drug delivery system for pulmonary applications and is therefore of particular interest for vaccine development in the Corona Pandemic. The biodegradable and biocompatible polymer's mucoadhesive, permeation-increasing and site-/cell-specific properties are useful in this context. Nanocarriers based on various microencapsulation and micro-nano mixing systems have already been developed. The aerodynamic character is important to enable efficient pulmonary aerosol formation and inhalation. In this article we present research on chitosan as pulmonary particulate anti-infective drug carrier.

Chitosan nanoparticles - potential drug delivery systems for COVID-19 drugs

Chitosan nanoparticles can deliver drugs to their specific target site and release them over a long period. In current corona crisis, chitosan nanoparticles could be one way to release potential COVID-19 drugs specifically in the lungs of affected patients. A potential drug delivery system for the treatment of SARS-CoV-2 infected persons is Novochizol™, consisting of chitosan-based nanoparticles.

Chitosan against Corona? Substituted chitosan as effective inhibitor of SARS-CoV-2 and MERS-CoV

The new corona virus SARS-CoV-2 has spread globally, originating from China since the beginning of the year. The pathogen causes the lung disease Covid-19 and has been classified as a pandemic since March 11, 2020. Researchers around the world are working on the development of effective vaccinations and drugs. A current study examined the antiviral effectiveness of HTCC (N- (2-hydroxypropyl) -3-trimethylammonium chitosan chloride) in vitro and ex vivo against the new coronavirus SARS-CoV-2 and MERS-CoV.

Congress and fairs

Meet us in person 2024:

  • 14th PBP World Meeting/ Research Pharm, Vienna, Austria, 18.-21.03.2024
  • CPHI, Milan, Italy, 08.-10.10.2024
  • MEDICA 2024, Düsseldorf, Germany, 11.-14.11.2024

To arrange an appointment please contact Katja Richter via This email address is being protected from spambots. You need JavaScript enabled to view it.

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact | GTC / Terms of Use | Legal info | Copyright © 2024 Heppe Medical Chitosan GmbH | Privacy notice

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.